Achaogen’s Therapeutic Antibody efforts are focused on developing monoclonal antibodies that are attractive as antibacterial agents
Therapeutic monoclonal antibodies (mAbs) have several distinguishing features that, we believe, make them attractive as antibacterial agents.
- Antibacterial mAbs are unlikely to be impacted by resistance mechanisms that inactivate existing small molecule-based antibiotics
- mAbs are highly specific to their target, greatly reducing the potential for toxicity due to off-target binding
- Humanized or fully human mAbs are likely to be well tolerated with low immunogenicity in patients
- mAb therapeutics may achieve sustained exposure with a typical half-life of around three weeks, potentially enabling an antibacterial antibody to prevent or cure an infection following a single intramuscular or intravenous dose
Achaogen has an early-stage mAb platform that could potentially lead to antibodies to treat infections caused by MDR Acinetobacter baumannii and other gram-negative pathogens. In May 2017, Achaogen announced that it had signed an agreement with the Bill & Melinda Gates Foundation to collaborate in efforts to prevent neonatal sepsis in developing countries through the generation of monoclonal antibody candidates targeting Acinetobacter baumannii, a leading cause of neonatal sepsis and a focus of Achaogen's internal bactericidal antibody program.
Based on our experience developing agents for gram-negative pathogens, we have identified a set of targets and a corresponding screening funnel for each target that we believe to be well suited for therapeutic mAb discovery. If successful, our unique approach has the potential to transform the way gram-negative infections are treated by enabling a safe, single-dose primary cure of infection or long-lasting step-down therapy upon discharge from the hospital.